Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass

Orion Corporation, Orion Pharma60 enrolled

Overview

The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.

Levosimendan or placebo infusion is started at the time of induction of anesthesia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Coronary Heart Disease

Interventions

levosimendanDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Three vessel coronary artery disease. * Indication for on-pump coronary artery bypass surgery. * Ejection fraction below 50% Exclusion Criteria: * Indication for any cardiac valve surgery * Previous coronary artery bypass surgery

Locations (2)

Helsinki University Central Hospital

Helsinki, Finland

Turku University Central Hospital

Turku, Finland

Outcomes

Primary Outcomes

Proportion of successful primary weanings

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.